Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$7.50 USD
-0.05 (-0.66%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $7.49 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VYGR 7.50 -0.05(-0.66%)
Will VYGR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
Other News for VYGR
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager announces selection of development candidate for GBA1 Program
Voyager Therapeutics Breaks Below 200-Day Moving Average - Notable for VYGR
NorthStar Appoints Peter Pfreundschuh to Board of Managers